— News and commentary from the endocrinology world
October 20, 2026 • 2 min read
Roughly a quarter of active-duty U.S. Army men had a single morning testosterone concentration under 300 ng/dL, a commonly used cutoff for low testosteroneopens in a new tab or window. (JAMA)
Nearly half of American women ages 40 to 60 reported menopausal symptomsopens in a new tab or window in 2025, and 15.6% of that group were taking prescription medications for those symptoms, a CDC report found.
One in six adults with type 1 diabetes reported moderate to severe depression or anxiety symptomsopens in a new tab or window, according to findings from the National Health Interview Survey. (Annals of Internal Medicine)
Greater weight reduction from GLP-1 receptor agonists and emerging multi-hormone receptor modulators was strongly linked to larger drops in blood pressureopens in a new tab or window, a meta-analysis of phase III trial data showed. (eClinicalMedicine)
Meanwhile, early research suggested GLP-1 agonists may have anti-aging potentialopens in a new tab or window. (CNN)
Novo Nordisk said its investigational weight-loss combination of semaglutide plus cagrilintide was associated with an average 25% weight lossopens in a new tab or window among women in post-hoc analyses of a phase III trial, with similar results across pre-, peri-, and postmenopausal stages.
Walmart plans to cover over 250 prescription drugsopens in a new tab or window -- including some insulins and GLP-1 drugs for diabetes -- at no cost for its employees in 2027. (CNBC)
In an analysis of Reddit users reporting use of the unapproved weight-loss drug retatrutideopens in a new tab or window, the most commonly cited adverse event terms included appetite increases, fatigue, increased energy, insomnia, increases in heart rate, and muscle-related symptoms. (JAMA Network Open)
Verdiva Bio canned a phase II studyopens in a new tab or window evaluating a once-weekly oral GLP-1 drug candidate, citing "market evolution." (FierceBiotech)
Zealand Pharma and Generate Biomedicines announced a collaboration to use artificial intelligenceopens in a new tab or window in developing novel protein-based therapies for obesity and metabolic diseases.